Clinical Trials Logo

Narcolepsy clinical trials

View clinical trials related to Narcolepsy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04820842 Terminated - Clinical trials for Narcolepsy Type 1 (NT 1)

A Study of TAK-994 in Adults With Narcolepsy

Start date: April 30, 2021
Phase: Phase 2
Study type: Interventional

Adults with narcolepsy who have completed the TAK-994-1501 study will be able to take part in this study. The main aim of this study is to check if participants have side effects from TAK-994. Participants will take one of 3 different TAK-994 dose for 8 weeks. Then, half the participants will continue with their dose of TAK-994 and half will take a placebo. In this study, a placebo will look like a TAK-994 tablet but will not have any medicine in it. Participants will take TAK-994 or placebo for 4 weeks. Participants will visit the clinic for a final check-up 2 weeks after their last dose of TAK-994 or placebo. The study doctors will check for side effects from TAK-994 and placebo throughout the study. Participants will continue to record any narcolepsy symptoms as they did in Part B of the TAK 994-1501 study.

NCT ID: NCT04096560 Terminated - Clinical trials for Narcolepsy Type 1 (NT1)

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Start date: February 27, 2020
Phase: Phase 2
Study type: Interventional

The main aims of the study are: - To check for side effects from TAK-994 and check what dose of TAK-994 participants can tolerate. - To check what dose range provides adequate relief of narcolepsy symptoms. - To check how much TAK-994 stays in the blood of participants, over time. The study will have 4 parts. Participants can only join 1 of the parts. A. Participants with type 1 narcolepsy will take either TAK-994 or placebo tablets for 28 days. A placebo looks just like TAK-994 but will not have any medicine in it. B. Participants with type 1 narcolepsy will take 1 of 3 doses of TAK-994 or placebo tablets for 56 days. C. Participants with type 1 narcolepsy in China only will take TAK-994 or placebo tablets for 56 days. D. Participants with type 2 narcolepsy will take either TAK-994 or placebo tablets for 28 days.

NCT ID: NCT01792583 Terminated - Clinical trials for Obstructive Sleep Apnea

The Nuvigil and Provigil Pregnancy Registry

Start date: June 30, 2009
Phase:
Study type: Observational [Patient Registry]

The primary objective of the Nuvigil/Provigil Pregnancy Registry is to characterize the pregnancy and fetal outcomes associated with Nuvigil and Provigil exposure during pregnancy.

NCT ID: NCT00366080 Terminated - Narcolepsy Clinical Trials

Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effectiveness and safety of the drug GSK189254 in treating patients with narcolepsy.